Drug Trial Radar · NCT03306394
A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).
Last checked: Nov 19, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
907
Actual
Start
Oct 18, 2016
Primary completion
Nov 30, 2020
Study completion Nov 30, 2020
Sponsor
- Lead sponsor
- Institut de Recherches Internationales ServierAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ADIR, a Servier Group company
- First posted
- Oct 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect additional safety and efficacy data during treatment with trifluridine / tipiracil in patients with a pretreated metastatic colorectal cancer (mCRC). Eligible patients may receive an early access to trifluridine / tipiracil through this clinical study until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor's prescription or can be accessed from another source or Sponsor decision.
Conditions
- Metastatic Colorectal Cancer
Interventions
Trifluridine/Tipiracil hydrochloride (S95005)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events [safety and tolerability]Time frame: Through 28 days following last administration of study medication
- Abnormalities in laboratory assessmentTime frame: Through study completion, an average of 12 weeks
- Abnormalities in performance status (ECOG)Time frame: Through study completion, an average of 12 weeks
- Abnormalities in vital signsTime frame: Through study completion, an average of 12 weeks
Locations
99 sites in 16 countries. Site status is shown where the registry gives one.
Chris O'Brien Lifehouse Oncology
Camperdown, Australia
St Vincent's Hospital The Kinghorn Cancer Centre
Darlinghurst, Australia
St Vincent's Hospital (Melbourne) Cancer Centre
Fitzroy, Australia
The Canberra Hospital Cancer,Ambulatory & Community Health Service (CACHS) Bldg 19
Garran, Australia
Royal Brisbane & Women's Hospital Clinical Research Unit
Herston, Australia
Cabrini Hospital Cabrini Haematology and Oncology Centre
Malvern, Australia
Perth Oncology - Mount Hospital
Perth, Australia
The Queen Elizabeth Hospital Haematology and Oncology Unit
Woodville, Australia
Hôpital Universitaire Erasme Gastro-Entérologie
Brussels, Belgium
Cliniques Universitaires St. Luc Oncologie médicale
Brussels, Belgium
Universitair Ziekenhuis Antwerpen Oncologie
Edegem, Belgium
U.Z. Gent Digestieve Oncologie
Ghent, Belgium
UZ Leuven Campus Gasthuisberg Digestieve Oncologie
Leuven, Belgium
Hospital Mãe de Deus Centro Intergrado de Pesquisa
Porto Alegre, Brazil
Clinicas Oncológicas Integradas (COI)
Rio de Janeiro, Brazil
AMO Assistencia Multidisciplinar em Oncologia GEM Assistencia Medica Especializada
Salvador, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP Núcleo de Pesquisa
São Paulo, Brazil
Hospital A C Camargo Unidade de Pesquisa Clínica
São Paulo, Brazil
Instituto Brasileiro de Controle do Câncer Unidadde de Pesquisa Clínica
São Paulo, Brazil
Complex oncology center - Plovdiv
Plovdiv, Bulgaria
Military Medical Academy - MHAT Oncology clinic
Sofia, Bulgaria
Specialized hospital for active treatment in oncology
Sofia, Bulgaria
SHAT of oncology diseases
Varna, Bulgaria
Klinicki bolnicki centar Rijeka Klinika za radioterapiju i onkologiju
Rijeka, Croatia
Klinicki bolnicki centar Zagreb Klinika za onkologiju
Zagreb, Croatia
Hopital Privé Les Bonnettes Pharmacie centrale
Arras, France
Institut Sainte Catherine Institut Sainte Catherine
Avignon, France
Centre de lutte contre le cancer Francois Baclesse UCP Digestif
Caen, France
Hôpital Trousseau Hépato-gastroentérologie et cancérologie digestive
Chambray-lès-Tours, France
CHU Hôpital du Bocage/ François Mitterrand Hépato-gastroentérologie
Dijon, France
CHU de Grenoble Oncologie médicale Hépato-gastroentérologie - 7D
Grenoble, France
CHD - Les Oudairies service d'hepato-gastroenterologie
La Roche-sur-Yon, France
Franco-British Institue Department of Medical Oncology
Levallois-Perret, France
Hopital Privé Jean Mermoz Service de Gastro entérologie et d'Oncologie médicale
Lyon, France
CRLCC Léon Bérard Service d'Oncologie
Lyon, France
CHU de la Timone Hépato-Gastro-Entérologie
Marseille, France
Hôpital Nord Franche-Comté - Site du Mittan Service d'oncologie médicale
Montbéliard, France
CRLCC Val d'Aurelle Oncologie Médicale
Montpellier, France
Centre Antoine Lacassagne Dpt d'Oncologie Médicale
Nice, France
Hôpital Saint-Antoine Service d'Oncologie Médicale
Paris, France
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.